Post Profile

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

The clinical benefit for patients with diverse types of metastatic cancers that has been observed upon blockade of the interaction between PD-1 and PD-L1 has highlighted the importance of this inhibitory axis in the suppression of tumour-specific T-cell responses. Notwithstanding the key role of PD-L1 expression by cells within the tumour micro-environment, our understanding of the regulation of the PD-L1 protein is limited.
read more


Related Posts

Integrative clinical genomics of metastatic cancer

Academics : Nature AOP

Clinical exome and transcriptome sequencing of 500 adult patients with metastatic solid tumours of diverse lineage and biopsy site, as part of the Michigan Oncology Sequencing (MI-ONCOSEQ) Program.

Nivolumab Immunotherapy Helps Patients with Advanced Bladder Cancer

Health : Newswise Medical News

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical tr...

Rutgers Cancer Institute of New Jersey Collaborates with Big Ten Cancer Research Consortium on Clinical Trial for Metastatic Kidney Cancer

Health : Newswise Medical News

In conjunction with the Big Ten Cancer Research Consortium, Rutgers Cancer Institute of New Jersey has opened a clinical trial for patients with metastatic kidney cancer. The study is examining a combination of pembrolizumab, a type...

Breast Cancer Clinical Trial to Test Combination of Heat Shock Protein Inhibitor and Hormonal Therapy

Health : Newswise Medical News

A clinical trial involving collaboration between researchers at Whitehead Institute and Dana Farber Cancer Institute is now enrolling patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer. The trial wi...

Nivolumab Shows Promise in First-Ever Trial for Patients with Refractory, Metastatic Anal Cancer

Health : Newswise Medical News

In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint blockade nivolumab shows promise for the...


Copyright © 2016 Regator, LLC